SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5847-5857

  Wen, Chun Chiang ^a   Cheng, Shih An ^a   Hsuen, Shu Ping ^a   Huang, Ya Ling ^a   Kuo, Zong Keng ^a   Lee, Hsin Fang ^a   Kuo, Chou Hua ^a   Du, Jia Ling ^a   Wang, Won Bo ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; POLYPEPTIDE; PROTEIN BCL 2; PROTEIN BCL XL; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENIC ACTIVITY; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SIMIAN VIRUS 40;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE THERAPY; HELA CELLS; HUMANS; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TRANSFECTION;

EID: 33745278867     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2109     Document Type: Article

References (49)

1. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217.
2. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-13.
3. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
6. Tyson FL, Boyer CM, Kaufman R, et al. Expression and amplification of the HER-2/neu (c-erbB-2) proto-oncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 1991;165:640-6.
7. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
8. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-74.
9. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64.
10. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48.
11. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999;19:6845-57.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
13. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-6.
14. Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-901.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
16. Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol 2004;31:9-20.
17. Yu DH, Scorsone K, Hung MC. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 1991;11:1745-50.
18. Matin A, Hung MC. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ 1993;4:1051-6.
19. Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997;14:561-8.
20. Brader KR, Wolf JK, Hung MC, et al. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res 1997;3:2017-24.
21. Xing X, Matin A, Yu D, et al. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. Cancer Gene Ther 1996;3:168-74.
22. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-33.
23. Sullivan CS, Pipas JM. T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol Mol Biol Rev 2002;66:179-202.
24. Shenk TE. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2265-300.
25. Lin YC, Peng JM, Wang WB. The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Oncogene 2000;19:2704-13.
26. Wang WB, Bikel I, Marsilio E, Newsome D, Livingston DM. Transrepression of RNA polymerase II promoters by the simian virus 40 small t antigen. J Virol 1994;68:6180-7.
27. Yaciuk P, Carter MC, Pipas JM, Moran E. Simian virus 40 large-T antigen expresses a biological activity complementary to the p300-associated transforming function of the adenovirus E1A gene products. Mol Cell Biol 1991;11:2116-24.
28. Montano X, Millikan R, Milhaven JM, et al. Simian virus 40 small tumor antigen and an amino-terminal domain of large tumor antigen share a common transforming function. Proc Natl Acad Sci U S A 1990;87:7448-52.
29. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-8.
30. Lin CT, Chan WY, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993;68:716-27.
31. Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci U S A 1994;91:8940-4.
32. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
33. Lin CS, Kuo HH, Chen JY, Yang CS, Wang WB. Epstein-Barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally. J Mol Biol 2000;303:7-23.
34. Wright M, Grim J, Deshane J, et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 1997;4:317-22.
35. Rob H, Pippin J, Drebin JA. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 2000;60:560-5.
36. Brodowicz T, Kandioler D, Tomek S, et al. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 2001;85:1764-70.
37. Jeschke M, Wels W, Dengler W, Imber R, Stocklin E, Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 1995;60:730-9.
38. Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 1997;57:3804-11.
39. Danielsen AJ, Maihle NJ. The EGF/ErbB receptor family and apoptosis. Growth Factors 2002;20:1-15.
40. Guo G, Wang T, Gao Q, et al. Expression of ErbB2 enhances radiation-induced NF-κB activation. Oncogene 2004;23:535-45.
41. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol 2003;22:875-81.
42. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408.
43. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3205-12.
44. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
45. Zhou Z, Jia SF, Hung MC, Heinerman ES. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001;61:3394-8.
46. Hunt KK, Deng J, Liu TJ, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997;57:4722-6.
47. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4.
48. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
49. Moulder SL, Yokes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.